RU2473554C2 - Слитые белки гормона роста - Google Patents
Слитые белки гормона роста Download PDFInfo
- Publication number
- RU2473554C2 RU2473554C2 RU2010103157/10A RU2010103157A RU2473554C2 RU 2473554 C2 RU2473554 C2 RU 2473554C2 RU 2010103157/10 A RU2010103157/10 A RU 2010103157/10A RU 2010103157 A RU2010103157 A RU 2010103157A RU 2473554 C2 RU2473554 C2 RU 2473554C2
- Authority
- RU
- Russia
- Prior art keywords
- polypeptide
- growth hormone
- seq
- fusion
- nucleic acid
- Prior art date
Links
- 239000000122 growth hormone Substances 0.000 title description 93
- 102000018997 Growth Hormone Human genes 0.000 title description 92
- 108010051696 Growth Hormone Proteins 0.000 title description 92
- 108090000623 proteins and genes Proteins 0.000 title description 13
- 102000004169 proteins and genes Human genes 0.000 title description 12
- 229920001184 polypeptide Polymers 0.000 claims abstract description 52
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 52
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 52
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 36
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 26
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 26
- 102100020948 Growth hormone receptor Human genes 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 20
- 206010056438 Growth hormone deficiency Diseases 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 239000000710 homodimer Substances 0.000 claims abstract description 14
- 108010068542 Somatotropin Receptors Proteins 0.000 claims abstract description 10
- 239000013598 vector Substances 0.000 claims abstract description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 24
- 239000000539 dimer Substances 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 11
- 230000001270 agonistic effect Effects 0.000 claims description 9
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 230000003442 weekly effect Effects 0.000 claims description 2
- 229940103526 Growth hormone receptor agonist Drugs 0.000 claims 1
- 210000001671 embryonic stem cell Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 6
- 239000000556 agonist Substances 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 4
- 230000004927 fusion Effects 0.000 description 81
- 238000002347 injection Methods 0.000 description 24
- 239000007924 injection Substances 0.000 description 24
- 108010033419 somatotropin-binding protein Proteins 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- 238000009396 hybridization Methods 0.000 description 15
- 102400001066 Growth hormone-binding protein Human genes 0.000 description 14
- 230000012010 growth Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 102000005962 receptors Human genes 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 10
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 10
- 230000004071 biological effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 239000005556 hormone Substances 0.000 description 8
- 229940088597 hormone Drugs 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 230000002354 daily effect Effects 0.000 description 7
- 230000003111 delayed effect Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 238000001426 native polyacrylamide gel electrophoresis Methods 0.000 description 6
- 101710099093 Growth hormone receptor Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 238000013103 analytical ultracentrifugation Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000006320 pegylation Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 101001075374 Homo sapiens Gamma-glutamyl hydrolase Proteins 0.000 description 4
- 101000664737 Homo sapiens Somatotropin Proteins 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102000023732 binding proteins Human genes 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 102000003675 cytokine receptors Human genes 0.000 description 3
- 108010057085 cytokine receptors Proteins 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 230000001817 pituitary effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 238000001134 F-test Methods 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- 206010070531 Foetal growth restriction Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101500028442 Homo sapiens Growth hormone-binding protein Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 101000599952 Mus musculus Insulin-like growth factor I Proteins 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101000599960 Rattus norvegicus Insulin-like growth factor I Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 101710106714 Shutoff protein Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- -1 alkaline earth metal salts Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 108700021031 cdc Genes Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000003509 long acting drug Substances 0.000 description 1
- 210000001699 lower leg Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000011421 subcutaneous treatment Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95112207P | 2007-07-20 | 2007-07-20 | |
| US60/951,122 | 2007-07-20 | ||
| GBGB0717985.6A GB0717985D0 (en) | 2007-07-20 | 2007-09-14 | Growth hormone fusion proteins |
| GB0717985.6 | 2007-09-14 | ||
| PCT/GB2008/002406 WO2009013461A1 (en) | 2007-07-20 | 2008-07-16 | Growth hormone fusion proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010103157A RU2010103157A (ru) | 2011-08-27 |
| RU2473554C2 true RU2473554C2 (ru) | 2013-01-27 |
Family
ID=38658989
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010103157/10A RU2473554C2 (ru) | 2007-07-20 | 2008-07-16 | Слитые белки гормона роста |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8293709B2 (enExample) |
| EP (1) | EP2170943A1 (enExample) |
| JP (1) | JP5546452B2 (enExample) |
| KR (1) | KR20100043201A (enExample) |
| CN (1) | CN101679504B (enExample) |
| AU (1) | AU2008278907B2 (enExample) |
| CA (1) | CA2693951A1 (enExample) |
| GB (1) | GB0717985D0 (enExample) |
| IL (1) | IL202225A (enExample) |
| RU (1) | RU2473554C2 (enExample) |
| WO (1) | WO2009013461A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0606946D0 (en) * | 2006-04-06 | 2006-05-17 | Asterion Ltd | Polypeptide antagonist |
| GB0717985D0 (en) * | 2007-07-20 | 2007-10-24 | Asterion Ltd | Growth hormone fusion proteins |
| GB0719818D0 (en) * | 2007-10-11 | 2007-11-21 | Asterion Ltd | Growth hormone fusion polypeptides |
| GB201104285D0 (en) | 2011-03-15 | 2011-04-27 | Asterion Ltd | Modified receptor fusion proteins |
| WO2013119800A1 (en) | 2012-02-07 | 2013-08-15 | Massachusetts Institute Of Technology | Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
| US9724396B2 (en) | 2013-03-15 | 2017-08-08 | Massachusetts Institute Of Technology | Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness |
| GB201316592D0 (en) * | 2013-09-18 | 2013-10-30 | Levicept Ltd | Fusion protein |
| US10317418B2 (en) | 2015-02-24 | 2019-06-11 | Massachusetts Institute Of Technology | Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness |
| GB201520021D0 (en) | 2015-11-13 | 2015-12-30 | Asterion Ltd | Fusion polypeptide |
| GB201706781D0 (en) | 2017-04-28 | 2017-06-14 | Univ Sheffield | Parathyroid hormone fusion polypeptide |
| EP3930687A4 (en) * | 2019-02-25 | 2023-06-07 | The University of Chicago | METHODS AND COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS USING ECM AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS |
| CN113880954B (zh) * | 2021-09-29 | 2024-05-14 | 江苏大学 | 一种重组人生长激素及其构建方法和应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU97102207A (ru) * | 1996-02-13 | 1999-02-27 | Джи-Си-Ар Фармасьютикалз Ко., Лтд. | Белок мутантного человеческого гормона роста, дезоксирибонуклеотид, экспрессионная плазмида, продукт экспрессии, антитело, лекарственные средства |
| GB2389115A (en) * | 2001-12-14 | 2003-12-03 | Asterion Ltd | Polypeptide having a plurality of modified growth hormone receptor binding domains from growth hormone |
| WO2004090135A2 (en) * | 2003-04-09 | 2004-10-21 | Asterion Limited | Cytokine polypeptides and antibodies containing a signal sequence for the attachement of glycosylphosphatidylinositol |
| WO2006010891A2 (en) * | 2004-07-26 | 2006-02-02 | Asterion Limited | Linkers |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2447632C (en) * | 2000-06-16 | 2011-08-02 | Asterion Limited | Fusion protein agonist comprising a growth hormone binding portion and an external domain of a growth hormone receptor |
| GB0606946D0 (en) | 2006-04-06 | 2006-05-17 | Asterion Ltd | Polypeptide antagonist |
| GB0717985D0 (en) * | 2007-07-20 | 2007-10-24 | Asterion Ltd | Growth hormone fusion proteins |
-
2007
- 2007-09-14 GB GBGB0717985.6A patent/GB0717985D0/en not_active Ceased
-
2008
- 2008-07-16 RU RU2010103157/10A patent/RU2473554C2/ru not_active IP Right Cessation
- 2008-07-16 AU AU2008278907A patent/AU2008278907B2/en not_active Ceased
- 2008-07-16 CA CA2693951A patent/CA2693951A1/en not_active Abandoned
- 2008-07-16 EP EP08775945A patent/EP2170943A1/en not_active Withdrawn
- 2008-07-16 JP JP2010516562A patent/JP5546452B2/ja not_active Expired - Fee Related
- 2008-07-16 US US12/669,451 patent/US8293709B2/en not_active Expired - Fee Related
- 2008-07-16 WO PCT/GB2008/002406 patent/WO2009013461A1/en not_active Ceased
- 2008-07-16 CN CN2008800214732A patent/CN101679504B/zh not_active Expired - Fee Related
- 2008-07-16 KR KR1020107002192A patent/KR20100043201A/ko not_active Withdrawn
-
2009
- 2009-11-19 IL IL202225A patent/IL202225A/en not_active IP Right Cessation
-
2012
- 2012-09-14 US US13/620,004 patent/US8470559B2/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU97102207A (ru) * | 1996-02-13 | 1999-02-27 | Джи-Си-Ар Фармасьютикалз Ко., Лтд. | Белок мутантного человеческого гормона роста, дезоксирибонуклеотид, экспрессионная плазмида, продукт экспрессии, антитело, лекарственные средства |
| GB2389115A (en) * | 2001-12-14 | 2003-12-03 | Asterion Ltd | Polypeptide having a plurality of modified growth hormone receptor binding domains from growth hormone |
| RU2004117777A (ru) * | 2001-12-14 | 2005-05-10 | Астерион Лимитед (Gb) | Модифицированный полипептид |
| WO2004090135A2 (en) * | 2003-04-09 | 2004-10-21 | Asterion Limited | Cytokine polypeptides and antibodies containing a signal sequence for the attachement of glycosylphosphatidylinositol |
| WO2006010891A2 (en) * | 2004-07-26 | 2006-02-02 | Asterion Limited | Linkers |
Also Published As
| Publication number | Publication date |
|---|---|
| US20130023477A1 (en) | 2013-01-24 |
| CN101679504A (zh) | 2010-03-24 |
| US8293709B2 (en) | 2012-10-23 |
| WO2009013461A1 (en) | 2009-01-29 |
| IL202225A0 (en) | 2010-06-16 |
| KR20100043201A (ko) | 2010-04-28 |
| AU2008278907B2 (en) | 2012-08-23 |
| RU2010103157A (ru) | 2011-08-27 |
| US20100197582A1 (en) | 2010-08-05 |
| CN101679504B (zh) | 2013-06-19 |
| IL202225A (en) | 2013-12-31 |
| US8470559B2 (en) | 2013-06-25 |
| JP5546452B2 (ja) | 2014-07-09 |
| JP2010534060A (ja) | 2010-11-04 |
| GB0717985D0 (en) | 2007-10-24 |
| WO2009013461A8 (en) | 2010-01-07 |
| CA2693951A1 (en) | 2009-01-29 |
| AU2008278907A1 (en) | 2009-01-29 |
| EP2170943A1 (en) | 2010-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008278907B2 (en) | Growth hormone fusion proteins | |
| CN107531806B (zh) | 融合蛋白 | |
| JP2020143155A (ja) | 持続型インスリンアナログ結合体及び持続型インスリン分泌ペプチド結合体を含む糖尿病治療用組成物 | |
| Datta-Mannan et al. | An engineered human follistatin variant: insights into the pharmacokinetic and pharmocodynamic relationships of a novel molecule with broad therapeutic potential | |
| US8637637B2 (en) | Fc fusion proteins of human growth hormone | |
| US20110177065A1 (en) | Methods of treating/preventing inflammation using combination of il-1 antagonist and il-18 binding protein | |
| CN110546159A (zh) | 甲状旁腺激素融合多肽 | |
| WO2024251200A1 (en) | Engineered il-7 variants and methods of use thereof | |
| RU2471808C2 (ru) | Полипептиды модифицированного гормона роста | |
| JP2014512810A (ja) | 改変受容体融合タンパク質 | |
| US20090270325A1 (en) | Growth factor | |
| WO2025183964A1 (en) | Methods of treating myostatin-related or activin a-related disorders using novel hybrid actriib ligand trap proteins | |
| CN116744959A (zh) | 肿瘤坏死因子-α和转化生长因子-β的双功能拮抗剂及其用途 | |
| HK1244019B (en) | Fusion proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20140717 |